Khoo C, Campos H, Judge H, Sacks F M
Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA.
J Lipid Res. 1999 Feb;40(2):202-12.
Apolipoproteins E and C-III are modulators of lipoprotein metabolism that could affect development of atherosclerosis. The prevalence in plasma of apoB-containing particles (LpB) that contain either apoE or apoC-III, both or neither, and the effect of estrogen on these lipoproteins are unknown. The LpB particle system, defined by the presence or absence of apoE or C-III, was studied in 13 normolipidemic women, 7 nonusers and 6 users of oral contraceptives. Fasting plasma was separated by anti-apoE and C-III affinity chromatography and ultracentrifugation into four types of VLDL, IDL, and LDL particles: with apoE but not apoC-III (E+C-), apoC-III but not apoE (E-C+), both (E+C+) or neither (E-C-). The predominant VLDL particles were E-C- (42% in nonusers, 56% in users) and E+C+ (39% in nonusers, 24% in users), suggesting that apoE and apoC-III mainly exist together in VLDL. In IDL, E-C- was the major fraction (74% nonusers, 81% users), and in LDL, it was 99% in both groups. The triglycerides in VLDL and IDL were mainly contained in C+ particles (79% and 66% of the total VLDL and IDL triglycerides, respectively). Within VLDL, IDL, and LDL, E-C- particles had the smallest size and E+C+ or E-C+ the largest. Users had higher concentrations of VLDL E-C- (280%) and IDL E-C- (90%) particles than nonusers. They also had higher free cholesterol and cholesteryl ester concentrations associated with these fractions and with VLDL E-C+. The triglyceride contents of VLDL E-C- particles were lower in users of oral contraceptives than in nonusers. This study demonstrates that the elevated VLDL TG concentrations in users of estrogen-dominant oral contraceptives is mainly caused by an increased concentration of small VLDL particles that have reduced TG content, and that do not have apoE and C-III. These particles may have lower atherogenicity than particles enriched with apoE and C-III.-Khoo, C., H. Campos, H. Judge, and F. M. Sacks. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content.
载脂蛋白E和C-III是脂蛋白代谢的调节因子,可能影响动脉粥样硬化的发展。含有载脂蛋白E或C-III、两者都含或两者都不含的含载脂蛋白B颗粒(LpB)在血浆中的患病率,以及雌激素对这些脂蛋白的影响尚不清楚。在13名血脂正常的女性、7名未使用口服避孕药者和6名口服避孕药使用者中,研究了由载脂蛋白E或C-III的存在与否定义的LpB颗粒系统。通过抗载脂蛋白E和C-III亲和色谱法和超速离心法将空腹血浆分离为四种类型的极低密度脂蛋白(VLDL)、中间密度脂蛋白(IDL)和低密度脂蛋白(LDL)颗粒:含载脂蛋白E但不含载脂蛋白C-III(E+C-)、含载脂蛋白C-III但不含载脂蛋白E(E-C+)、两者都含(E+C+)或两者都不含(E-C-)。主要的VLDL颗粒是E-C-(未使用者中占42%,使用者中占56%)和E+C+(未使用者中占39%,使用者中占24%),这表明载脂蛋白E和C-III主要共同存在于VLDL中。在IDL中,E-C-是主要部分(未使用者中占74%,使用者中占81%),在LDL中,两组均为99%。VLDL和IDL中的甘油三酯主要存在于C+颗粒中(分别占总VLDL和IDL甘油三酯的79%和66%)。在VLDL、IDL和LDL中,E-C-颗粒尺寸最小,E+C+或E-C+颗粒尺寸最大。使用者的VLDL E-C-颗粒(280%)和IDL E-C-颗粒(90%)浓度高于未使用者。他们与这些组分以及VLDL E-C+相关的游离胆固醇和胆固醇酯浓度也更高。口服避孕药使用者的VLDL E-C-颗粒中的甘油三酯含量低于未使用者。这项研究表明,以雌激素为主的口服避孕药使用者中VLDL甘油三酯浓度升高主要是由于小VLDL颗粒浓度增加,这些颗粒的甘油三酯含量降低,且不含载脂蛋白E和C-III。这些颗粒的致动脉粥样硬化性可能低于富含载脂蛋白E和C-III的颗粒。—— Khoo, C., H. Campos, H. Judge, and F. M. Sacks. 雌激素口服避孕药对由载脂蛋白E和C-III含量定义的脂蛋白B颗粒系统的影响